The coronavirus disease 2019 (COVID-19) caused by the infection of severe acuterespiratory syndrome coronavirus 2 (SARS-CoV-2)，resulting in more than 82 millionconfirmed cases and caused around 1.8 million deaths, as of 2 January 2021. The ongoingpandemic still poses unprecedented global threat to public health system worldwide. OnDecember 31, 2020, the joint prevention and control agency of China Council announcedthat Sinopharm SARS-CoV-2 inactivated vaccine had been conditionally approved by NationalMedical Products Administration, and the protection rate was 79.34%. So far, more than198 vaccines were currently in preclinical or clinical development. The investigatorsaimed to initiate an observational cohort of healthy individuals injected with SARS-CoV-2Vaccine, which will perform a longitudinal, comprehensive analysis of the SARS-CoV-2vaccine Induced adaptive immune responses.
Inclusion Criteria:
- Healthy and aged between 18 to 59 years
Exclusion Criteria:
- High-risk epidemiology history within 14 days before enrollment
- SARS-CoV-2 specific IgG or IgM positive in serum
- Positive PCR test for SARS-CoV-2 from pharyngeal or anal swab samples
- Axillary temperature of more than 37·0°C
- Known allergy to any vaccine component
- Thyroid disease
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
Investigator: Yuxin Chen
Investigator: Chao Wu
Chao Wu, M.D., Ph.D
+8613809022921
dr.wu@nju.edu.cn
Yuxin Chen, Ph.D
+8617714413628
yuxin_chen2015@163.com